Encompass Health Corp. announced it will release its financial results for the third quarter ending September 30, 2026, after market close on October 28. The company will hold an investor conference call on October 29 to discuss the results. Encompass Health is a leading operator of inpatient rehabilitation hospitals in the U.S., with 177 hospitals across 39 states and Puerto Rico. This earnings report will provide insight into the company's performance and outlook in the healthcare sector.
Encompass Health's upcoming 2026 third-quarter earnings call is noted here alongside current health sector market data. For readers following health stocks, as of Oct 02, 2026 01:31 WIB, 22 of 100 priced US health-sector stocks on Pluang rose while 76 fell. Among movers, ClearPoint Neuro Inc (CLPT) traded at USD 11.59 with a 5.08% decline and a typical hold time of 9 days, contrasting with Bio-Rad Laboratories (BIO) at USD 359.44 down 4.84% held for 58 days, and American Well Corp (AMWL) at USD 12.93 down 4.79% held for 61 days.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
